[New opportunities of antithrombotic therapy in patients with type 2 diabetes mellitus and stable coronary heart disease for reducing the cardiovascular risk and cardiovascular complications: THEMIS, THEMIS-PCI trials].
V Y KalashnikovM S MichurovaPublished in: Terapevticheskii arkhiv (2022)
Patients with diabetes mellitus (DM) and coronary heart disease belong to a group with a very high risk of developing cardiovascular disease. In patients with coronary atherosclerosis, DM increases the risk of ischemic events by 2-4 times. Apparently, increased antithrombotic therapy has an advantage in patients with DM who have had myocardial infarction. However, until recently it was not clear there is such an advantage in patients with DM and stable coronary artery disease without prior myocardial infarction. The addition of ticagrelol to monotherapy of acetylsalicylic acid reduces the risk of major cardiovascular events in patients with type 2 DM and stable coronary artery disease undergoing percutaneous coronary intervention, if patients have a high risk of ischemic events.
Keyphrases
- coronary artery disease
- cardiovascular events
- percutaneous coronary intervention
- cardiovascular disease
- coronary artery bypass grafting
- st segment elevation myocardial infarction
- glycemic control
- st elevation myocardial infarction
- acute myocardial infarction
- atrial fibrillation
- heart failure
- end stage renal disease
- antiplatelet therapy
- left ventricular
- ejection fraction
- acute coronary syndrome
- newly diagnosed
- type diabetes
- prognostic factors
- chronic kidney disease
- risk factors
- aortic stenosis
- ischemia reperfusion injury
- patient reported outcomes
- clinical trial
- stem cells
- metabolic syndrome
- cerebral ischemia
- transcatheter aortic valve replacement
- oxidative stress
- coronary artery bypass
- cardiovascular risk factors
- combination therapy